Steinberg Sarit
Directeur des opérations chez Israel Biotech Fund
Profil
Sarit Steinberg is a Partner at Israel Biotech Fund since 2015.
Prior to this, she worked as the General Counsel at Immune Pharmaceuticals Ltd.
from 2013 to 2015.
Ms. Steinberg holds a graduate degree from the London School of Economics & Political Science (2003) and a graduate degree from Queen Mary University of London (2002).
Postes actifs de Steinberg Sarit
| Sociétés | Poste | Début |
|---|---|---|
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Directeur des opérations | 01/02/2020 |
Anciens postes connus de Steinberg Sarit
| Sociétés | Poste | Fin |
|---|---|---|
Immune Pharmaceuticals Ltd.
 Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | Conseiller Juridique Général | 01/05/2015 |
Formation de Steinberg Sarit
| London School of Economics & Political Science | Graduate Degree |
| Queen Mary University of London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Immune Pharmaceuticals Ltd.
Immune Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million. | Health Technology |
